SCHEMBL4465602

SCHEMBL4465602

Clc1ccc(C(Cl)(Cl)c2ccc(Cl)cc2Cl)c(Cl)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 7/20 0.73
CYP3A4 P08684 4/20 0.73
TDP1 Q9NUW8 4/20 0.73
MAPK1 P28482 3/20 0.73
TP53 P04637 3/20 0.50
HSD17B10 Q99714 2/20 0.44
IDO1 P14902 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CASP1 P29466 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AHR P35869 1/20 0.38
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
CASR P41180 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11869739 0.89 TSHR (0.65) TSHRCYP3A4TDP1MAPK1TP53
SCHEMBL3218519 0.86 TSHR (0.61) TSHRCYP3A4TDP1MAPK1TP53
SCHEMBL1845000 0.84 TSHR (1.00) TSHRCYP3A4TDP1MAPK1TP53
SCHEMBL29402968 0.84 TSHR (1.00) TSHRCYP3A4TDP1MAPK1TP53
SCHEMBL6203055 0.83 TSHR (0.57) TSHRCYP3A4TDP1MAPK1TP53
SCHEMBL3206408 0.82 CYP3A4 (0.52) TSHRCYP3A4TDP1MAPK1TP53
SCHEMBL11870624 0.81 TSHR (0.55) TSHRCYP3A4TDP1MAPK1TP53
SCHEMBL3222632 0.80 TSHR (0.53) TSHRCYP3A4TDP1MAPK1TP53
SCHEMBL11865542 0.79 TSHR (0.52) TSHRCYP3A4TDP1MAPK1TP53
SCHEMBL10907163 0.78 TSHR (0.64) TSHRCYP3A4TDP1MAPK1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576088-B2 Benzodioxole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
EP-1532132-B1 NOVEL BENZODIOXOLES HOFFMANN LA ROCHE (CH) 2008-03-19 EP disclosed
US-20050143373-A1 Benzodioxole derivatives ALANINE ALEXANDER (FR) 2005-06-30 US disclosed
US-6900227-B2 Benzodioxole derivatives HOFFMANN-LA ROCHE INC. (US) 2005-05-31 US disclosed
EP-1532132-A1 NOVEL BENZODIOXOLES F.HOFFMANN-LA ROCHE AG (CH) 2005-05-25 EP disclosed
US-20040142922-A1 Benzodioxole derivatives HOFFMANN-LA ROCHE INC. 2004-07-22 US disclosed
WO-2004013120-A1 NOVEL BENZODIOXOLES F. HOFFMANN-LA ROCHE AG (CH) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143373-A1 Benzodioxole derivatives CNR2, CNR1, GPR119 TSHR 1029/4885CYP3A4 313/4885TDP1 4429/4885
US-20040142922-A1 Benzodioxole derivatives CNR1, CNR2, GPR119 TSHR 1171/4885CYP3A4 273/4885TDP1 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.